Hyperkalemia during spironolactone use in patients with decompensated heart failure.
BACKGROUND
The incidence of hyperkalemia related to spironolactone use is low in stable heart failure; however, it has not been studied during decompensation.


OBJECTIVE
To evaluate the influence of spironolactone on serum potassium in decompensated heart failure (HF).


METHODS
In a cohort study, patients that had been hospitalized due to decompensated HF, with left ventricular ejection fraction (LVEF) < 0.45 and serum potassium between 3.5 and 5.5 mEq/l were selected. The patients were divided according to spironolactone use (Group S) or no use (Group C). The outcome was potassium increase (> 6.0 mEq/l) and the use of calcium polystyrene. A multivariate analysis through logistic regression was carried out and values of p < 0.05 were considered significant.


RESULTS
A total of 186 patients (group S: 56; group C: 130) were studied; LVEF of 0.25, aged 55.5 years and 65.2% of them males. The incidence of hyperkalemia was 10.7% in group S and 5.4% in group C (p = 0.862). The multivariate analysis showed that serum urea > 60.5 mg/dl during the hospitalization presents a relative risk of 9.6 (95%CI 8.03 - 11.20; p = 0.005) for the occurrence of hyperkalemia.


CONCLUSIONS
The incidence of hyperkalemia was two-fold higher with spironolactone use, but it was not statistically significant. The increase in urea levels was associated to the hyperkalemia. Randomized studies are necessary to clarify this issue.
Lima
Marcelo Villaça
MV
Hospital Auxiliar de Cotoxó, São Paulo, Brasil. villacalima@cardiol.br
Ochiai
Marcelo Eidi
ME
Cardoso
Juliano Novaes
JN
Morgado
Paulo César
PC
Munhoz
Robinson Tadeu
RT
Barretto
Antonio Carlos Pereira
AC
D001938:Brazil / Q000453:epidemiology; D004812:Epidemiologic Methods; D005260:Female; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D006947:Hyperkalemia / Q000097:blood / Q000139:chemically induced* / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D011188:Potassium / Q000097:blood; D013148:Spironolactone / Q000009:adverse effects* / Q000627:therapeutic use; D014508:Urea / Q000097:blood
D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D014508:Urea; D011188:Potassium